ATRAID

Across TCGA pan-cancer cohorts, ATRAID mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATRAID data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATRAID mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATRAID expression acts as an unfavorable survival marker.

CCRCC, PDAC, and COAD are the cancer types where ATRAID mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.567	0.895	.001	81	view →
PDAC	OS	Tertile	III,IV	0.409	0.960	.006	13	view →
COAD	DFS	Median	II,III,IV	0.874	1.000	.031	12	view →
HNSC	DFS	Tertile	All	0.367	1.000	.028	6	view →
LUAD	OS	Median	All	0.765	0.963	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATRAID–CCRCC (DFS)

Open the CCRCC breakdown →